Trouver des essais cliniques
A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants
Code de protocole Servier:
S095032-234
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S.)
Identifiant Clinicaltrials.gov:
NCT07235774
Trouver un site de recrutement
Comment participer à cette étude
Si vous pensez être éligible pour cette étude (voir
ci-dessous), vous pouvez identifier le site le plus proche de chez vous et le contacter directement. Si vous ne trouvez pas de site près de chez vous, veuillez contacter l'Institut de Recherches Internationales Servier (I.R.I.S.).
critères d'éligibilité
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Ceux-ci comprennent les critères d'inclusion et les critères d'exclusion. Parmi ces critères, on peut citer l'état de santé général d'une personne ou les traitements antérieurs qu'elle a suivis.
Nom:
Institut de Recherches Internationales Servier, Département des études cliniques
Numéro de téléphone:
+33 1 55 72 60 00
L'étude a 1 centre
Description de l'étude
The objective of this study is to evaluate the effect of multiple oral doses of vorasidenib on the single dose pharmacokinetics of the representative combined oral contraceptive, drospirenone (DRSP)/ethinyl estradiol (EE), in healthy female participants. The study includes a screening phase, two treatment periods in-house, and a follow-up period. During the first period, from Day 1 through Day 5, participants will take one dose of DRSP/EE. In the second treatment period, from Day 6 through Day 24, participants will take vorasidenib every day, and on Day 20, they will take DRSP/EE along with vorasidenib. The entire study, including screening and follow-up, will last up to 83 days. Participants may undergo blood tests, heart tests (electrocardiogram (ECG)), vital sign checks, and physical exams.
Titre officiel: A Phase 1, Open-label, Single-sequence, 2-period Study to Determine the Effects of Repeated Oral Dosing of Vorasidenib on the Pharmacokinetics, Safety and Tolerability of a Combined Oral Contraceptive in Healthy Female Participants.
Indications
Healthy Adult Female Participants
Interventions / Traitements
Le ou les traitements administrés aux participants à l'étude.
- Vorasidenib
- DRSP/EE
Autres numéros d'identification
Autres numéros d'identification sous lesquels l'étude peut être connue.
- S095032-234
Critères d'éligibilité
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Ceux-ci comprennent les critères d'inclusion et les critères d'exclusion. Parmi ces critères, on peut citer l'état de santé général d'une personne ou les traitements antérieurs qu'elle a suivis.
Age éligible pour l’étude
18 ans à 55 ans
(Adulte)
Sexe
FemmeAccepte les volontaires en bonne santé
Oui- * Healthy, nonpregnant, nonlactating pre- or post-menopausal female participants, including women of childbearing potential (WOCBP), assigned female at birth only.
- * 18 - 55 years of age (both inclusive) at Screening.
- * Body mass index (BMI) of 18.0 - 30.0 kg/m² (both inclusive) at Screening.
- * Body weight of at least 40 kg at Screening.
- * Participants of childbearing potential who must use two effective methods of birth control (e.g., non-hormonal intrauterine device [IUD], male or female condom with spermicide, cap, diaphragm, or sponge with spermicide), or abstinence, from Screening until at least 90 days after the last dose of vorasidenib or who must be surgically sterile (e.g., hysteroscopic sterilization, bilateral tubal salpingectomy, hysterectomy, or bilateral oophorectomy) at least 6 months prior to the first dose of IMP in the study. Participants of childbearing potential must have a negative serum pregnancy test at Screening and prior to the first dose of IMP in the study.
- * Post-menopausal participants (defined as amenorrhea for 12 consecutive months and documented plasma follicle stimulating hormone [FSH] level > 40 IU/mL) who must have a FSH test confirming the post-menopausal status at Screening.
- * A continuous nonsmoker who has not used nicotine-containing products (e.g., snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) for at least 3 months prior to the first dose of IMP in the study based on a cotinine test result.
- * Participants who are considered by the Investigator to be in good general health as determined by medical history, full physical examination, clinical laboratory test results, 12-lead electrocardiogram (ECG) results, and vital sign measurements findings at Screening and Admission.
- * Participants of childbearing potential who are pregnant, lactating, or planning to become pregnant within at least 90 days after the last dose of vorasidenib; the participants who are on oral contraceptive pills or contraceptive patch within 31 days prior to the first dose of IMP in the study; participants who use a hormonal IUD or vaginal ring within 3 months prior to the first dose of IMP in the study; or participants who receive any injectable or implantable hormone containing product within 1 year prior to the first dose of IMP in the study.
- * Participant who consume grapefruit or grapefruit juice, or Seville orange or Seville orange-containing products (e.g., marmalade), within 14 days prior to the first dose of IMP in the study.
- * Participant who ingest vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, and mustard) and charbroiled meats within 14 days prior to the first dose of IMP in the study.
- * Participant who consume caffeine- or xanthine-containing products (e.g., coffee, tea, cola drinks, and chocolate), alcohol, or products containing any of these within 48 hours prior to the first dose of IMP in the study.
- * Participants who are unable or unwilling to abstain from recreational drugs, alcohol, caffeine, xanthine-containing beverages or food (e.g., coffee, tea, chocolate, and caffeinated sodas, colas), grapefruit, grapefruit juice, Seville oranges, or products containing any of these from 48 hours (caffeine, xanthine-containing beverages or food, alcohol) or 14 days (recreational drugs, grapefruit, grapefruit juice, Seville oranges, or Seville orange-containing products) prior to the first dose of IMP in the study until the Discharge/Early Termination visit.
- * In the opinion of the Investigator, participants who are not suitable for entry into the study.
- * Participant who have received any vaccine or used any prescription (including hormone replacement therapy) or over-the-counter medications (except acetaminophen/paracetamol [up to 2 g per 24 hours] or ibuprofen [up to 1.2 g per 24 hours]), including herbal (e.g., St. John's Wort) or nutritional supplements, within 14 days or 5 drug half-lives, whichever is longer, prior to the first dose of IMP in the study.
Comment l'étude est-elle conçue ?
Allocation
Comment les participants sont répartis dans différents groupes. La répartition peut être aléatoire (randomisée) ou prédéterminée (non randomisée). Randomisée signifie que les participants sont répartis de manière aléatoire dans leur groupe/branche.
Modèle d'étude interventionnelle
Comment les traitements sont administrés et testés dans le cadre d'une étude.
Groupe unique
Une étude à groupe unique consiste à étudier un groupe de participants qui reçoivent tous le même traitement. Les chercheurs observent les résultats du groupe afin de comprendre les effets du traitement.
Groupe de participants / Bras de traitement
Un groupe de participants à l'étude qui reçoivent le même traitement ou la même intervention.
Intervention / Traitement
Le ou les traitements administrés aux participants à l'étude.
Groupe de participants / Bras de traitement
Un groupe de participants à l'étude qui reçoivent le même traitement ou la même intervention.
Expérimental:
Vorasidenib and drospirenone (DRSP)/ethinyl estradiol (EE)
Participants will receive a single oral dose of 3 mg DRSP/0.02 mg EE on Day 1.
Participants will receive an oral daily dose of 40mg vorasidenib from Day 6 to Day 24. In addition, participants will receive a single oral dose of 3 mg DRSP/0.02 mg EE on Day 20, co-administered with vorasidenib.
Intervention / Traitement
Le ou les traitements administrés aux participants à l'étude.
Traitement:
Vorasidenib
40mg taken orally daily from Day 6 through Day 24
Traitement:
DRSP/EE
3 mg DRSP/0.02 mg EE taken orally on Day 1 and Day 20